Serum angiopoietin-2 concentrations of post-PCI are correlated with the parameters of renal function in patients with coronary artery disease

Wen Jian, MDa,b,c, Lang Li, MD, PhDa,b,c, Xiao-Min Wei, MDd, Jia-Hui Guan, MDe, Guo-Liang Yang, MDa,b,c, Chun Gui, MD, PhDa,b,c,*

Abstract

Patients with coronary artery disease (CAD) frequently have comorbidity of chronic kidney disease (CKD). Their renal function may deteriorate because of the use of contrast agent after percutaneous coronary intervention (PCI). Angiopoietin-2 (Ang-2), which is highly expressed in the site of angiogenesis, plays an important role in both CAD and CKD. This study aimed to investigate the relation of serum Ang-2 concentrations with the renal function after PCI.

This study enrolled 57 patients with CAD undergoing PCI. Blood samples for Ang-2 were collected in the first morning after admission and within 24 to 48 h after PCI. The parameters of renal function (serum creatinine, cystatin C and eGFR) were tested on the first day after admission and within 72 h after PCI.

Overall, serum Ang-2 levels of post-PCI were significantly lower than those of pre-PCI (median, 1733 (IQR, 1100–2568) vs median, 2523 (IQR, 1702–3640) pg/mL; P < 0.001). However, in patients with CKD (eGFR < 60 mL/min/1.73 m²), there was no significant difference between serum Ang-2 levels of post-PCI and those of pre-PCI (median, 2851 (IQR, 1720–4266) vs. median, 2492 (IQR, 1434–4994) pg/mL; P = .925). In addition, serum Ang-2 levels of post-PCI, but not pre-PCI, were significantly correlated with the post-PCI parameters of renal function.

Serum Ang-2 concentrations of post-PCI are closely related to renal function in patients with CAD. It may have potential to be the early biomarker of contrast-induced nephropathy in the future.

Abbreviations: AKI = acute kidney injury, Ang-1 = angiopoietin-1, Ang-2 = angiopoietin-2, CAD = coronary artery disease, CIN = contrast-induced nephropathy, CKD = chronic renal disease, CVD = cardiovascular disease, CysC = cystatin C, eGFR = estimated glomerular filtration rate, IQR = interquartile range, miRNAs = microRNAs, NGAL = neutrophil gelatinase-associated lipocalin, PCI = percutaneous coronary intervention, ROS = reactive oxygen species, Scr = serum creatinine, SD = standard deviation, STEMI = ST-elevation myocardial infarction, TNF-α = tumor necrosis factor-α, UTI = urinary tract infection.

Keywords: angiopoietin-2, biomarker, chronic kidney disease, coronary artery disease, percutaneous coronary intervention

1. Introduction

Coronary artery disease (CAD) is the most common cause of death globally. Limitation of blood flow to the heart can cause ischemia and dysfunction of the myocardial cells. Angiogenesis, which occurs in the site of anoxic tissue, can lead to the formation of new blood vessels and is crucial for the self-compensation in response to ischemia from coronary stenosis or occlusion.[1] Several growth factors are closely associated with angiogenesis such as angiopoietin-1 (Ang-1), angiopoietin-2 (Ang-2), and vascular endothelial growth factor. The angiopoietin/Tie-2 ligand receptor system is an important regulator of the vascular integrity and angiogenesis.[2] Binding of the agonist Ang-1 to the Tie2 receptor promotes vascular stabilization,[3] whereas Ang-2 inhibits binding of Ang-1 to Tie2 disrupting the Tie2 signaling. High level of Ang-2 can result in the destabilization of endothelial cell junctions to enhance new vessel branching and sprouting.[4] Ang-2 is stored in the Weibel-Palade bodies within the endothelial cells and can be rapidly released upon various stimuli.[5] Ang-2 expression is significantly up-regulated in ischemic or necrotic myocardium.[1,5] Clinical studies have indicated that peripheral blood Ang-2 concentrations are elevated in patients with CAD and are associated with the severity of coronary artery stenosis.[6,7]

Of note, because of lots of common risk factors, a great number of patients with CAD have varying degrees of chronic kidney disease (CKD). The heart failure caused by CAD can also lead to renal insufficiency. In addition, it is reported that CKD patients have higher risk of developing cardiovascular disease (CVD), which indicate the highly interrelated feature of them.[9,10] Ang-2, besides its role in angiogenesis, also controls
the vascular inflammation\(^{[11]}\) and plays an important role in CKD. Pathophysiological characteristics of CKD, such as hypoxia, tumor necrosis factor-\(\alpha\) (TNF-\(\alpha\)), and reactive oxygen species (ROS), can lead to endothelial Ang-2 secretion;\(^{[11]}-^{[13]}\) Serum Ang-2 levels increase with progression of CKD and are closely related to development of fibrosis.\(^{[11]}\)

Even in the general population, after exclusion of subjects with hypertension or diabetes mellitus, serum Ang-2 concentrations are also highly associated with the parameters of renal function.\(^{[16]}\)

In vivo, glomerular Ang-2 is increased in glomerulonephritis.\(^{[17]}\) In renal ischemia/reperfusion injury, Ang-2 is highly expressed and involved in renal microvascular remodeling and development of fibrosis.\(^{[18]}\)

Our previous study showed that serum Ang-2 concentrations are elevated in patients with CAD and decrease significantly after percutaneous coronary intervention (PCI).\(^{[1]}\) However, there are still some patients whose Ang-2 levels decrease slightly or even increase after PCI, which exact mechanisms remain unclear. Given the fact that lots of patients with CAD have a certain degree of renal insufficiency, and their renal functions may deteriorate during the process of PCI because of the use of contrast agent. Therefore, in addition to the relief of myocardial ischemia, the status of renal function may also influence the serum Ang-2 level of post-PCI. Based on the prior data, we hypothesized that Ang-2 level of post-PCI may have close relations with renal function.

Given the above information, this study aimed to determine whether serum Ang-2 levels of post-PCI are correlated with renal-function parameters [serum creatinine (Scr), cystatin C (CysC) and estimated glomerular filtration rate (eGFR)] of pre-PCI or post-PCI.

2. Methods

2.1. Patients and study design

This study enrolled 57 patients with CAD undergoing PCI. The following exclusion criteria were defined: ST-elevation myocardial infarction (STEMI), valvular heart disease, systemic infectious diseases, tumor and autoimmune diseases. The study protocol was reviewed and approved by the Human Research Ethics Committee of the First Affiliated Hospital of Guangxi Medical University, China. Written informed consents were obtained from all patients. The clinical data of patients were collected on the first day after admission. Standard medical treatments were given to all patients for their clinical conditions. All patients were used of the drug-eluting stent, and the dosage of contrast agent was used as needed.

2.2. Laboratory measurements

The result of Scr and CysC were collected on the data of the routine laboratory test of the hospital on the first day after admission and within 72 h after PCI. eGFR was calculated using CKD-EPI\(_{\text{Scr, CysC}}\) equation.\(^{[19]}\) Venous blood samples for Ang-2 were collected in the first morning after admission and within 24 to 48 h after PCI. The samples were kept at -80°C until it was used for analysis. According to the manufacturer’s instructions of enzyme-linked immunosorbent assay kits (RayBiotech, Inc, Norcross, GA), Ang-2 concentrations were measured in duplicate and averaged.

2.3. Statistical analysis

Continuous variables are presented as mean ± SD or median (IQR, interquartile range), and were compared using the Student \(t\) test or the Mann-Whitney U test, as appropriate. Categorical variables were compared using the chi-square or the Fisher exact test. The distribution of Ang-2, which was verified by Kolmogorov–Smirnov test, was skewed. To determine whether there was difference in serum Ang-2 levels before and after PCI, the Wilcoxon signed-rank test was used. The correlations of serum Ang-2 levels with the renal-function parameters were analyzed using the Spearman rank correlation test. \(P\) values < .05 were considered statistically significant. The statistical analysis was conducted using SPSS, version 19.

3. Results

3.1. Patient characteristics

The baseline characteristics of patients with CAD are summarized in Table 1. Based on the eGFR levels of pre-PCI, the patients were divided into CKD group \((\text{eGFR} < 60 \text{mL/min/1.73 m}^2)\) and non-CKD group \((\text{eGFR} \geq 60 \text{mL/min/1.73 m}^2)\). No significant difference was found between the groups in terms of gender, BMI, diabetes, hyperlipidemia, smoking, left ventricular ejection fraction, myocardial enzyme, lesion vessel features, treated vessels numbers and all the medications at admission. However, the CKD patients were characterized by an older age and higher blood pressure. Of note, the patients with CKD had similar Ang-2 levels of pre-PCI \([\text{median, 2492 (IQR, 1434–4994) pg/mL; } P = .911]\), but significant higher Ang-2 levels of post-PCI \([\text{median, 2851 (IQR, 1720–4286) vs median, 1552 (IQR, 1043–2438) pg/mL; } P = .013]\) compared with the non-CKD patients.

3.2. Changes in serum angiopoietin-2 levels after PCI

There was no clinical evidence of interventional complications during the process of PCI. Overall, serum Ang-2 levels of post-PCI were significantly lower than those of pre-PCI \([\text{median, 1733 (IQR, 1100–2568) vs. median, 2523 (IQR, 1702–3640) pg/mL; } P < .001]\). However, as shown in Figure 2, in patients with CKD, there was no significant difference between serum Ang-2 levels of post-PCI and those of pre-PCI \([\text{median, 2851 (IQR, 1720–4286) vs median, 2492 (IQR, 1434–4994) pg/mL; } P = .925]\).

3.3. Correlation of the serum Ang-2 with the parameters of renal function

By Spearman rank correlation test, serum Ang-2 levels of pre-PCI were unrelated to any parameter of renal function (data were not shown). However, as can be seen from Figure 2, serum Ang-2 levels of post-PCI were significantly correlated with the renal-function parameters of post-PCI \([\text{Scr, } r = 0.283, P = .033; \text{CysC, } r = 0.289, P = .029; \text{eGFR, } r = -0.289, P = .029]\). However, for the renal-function parameters of pre-PCI, only Scr levels were found to be correlated with serum Ang-2 levels of post-PCI \((r = 0.318, P = .016)\).

4. Discussion

The major findings of the present study are:

1. serum Ang-2 levels of post-PCI are significantly correlated with the renal-function parameters of post-PCI.
Angiographic characteristics

Contrast-induced nephropathy (CIN), we still observed because of the small sample size and the low incidence of that only the renal-function parameters of post-PCI, not pre-PCI, serum Ang-2 levels of post-PCI. Before the study, we assumed that the status of renal function may turn to be major in and the different extent of renal injury by contrast agent, the evidence mentioned above, we can deduce that both ischemic especially the ones with renal dysfunction. Based on all the correlation between the Scr of pre-PCI and the Ang-2 of post-PCI. Further study which enlarges the sample size will make the results more accurate.

This study indicated the complexity of Ang-2 in CAD patients, especially the ones with renal dysfunction. Based on all the evidence mentioned above, we can deduce that both ischemic myocardium and dysfunctional kidney contribute to the changes seen in acute kidney injury (AKI). Scr levels start to rise >50% number of nephrons are reabsorbed and catabolized by the proximal tubules. Serum cystatin C levels are less affected by non-renal factors, and have been demonstrated to be a more accurate early biomarker of GFR reduction compared with Scr. It has been found that elevated serum cystatin C level is an independent predictor of CIN. Neutrophil gelatinase-associated lipocalin (NGAL), a 25-kDa

Table 1

Baseline characteristics of CKD group and non-CKD group.

|                              | CKD group (n=14) | Non-CKD group (n=43) | P value |
|------------------------------|------------------|----------------------|---------|
| **Clinical characteristics** |                  |                      |         |
| Age (year)                   | 70.64±7.31       | 55.09±9.69           | <.001   |
| BMI (kg/m²)                  | 24.87±3.18       | 24.15±2.92           | .439    |
| Male gender                  | 9 (64%)          | 35 (81%)             | .338    |
| Hypertension                 | 12 (86%)         | 20 (47%)             | .010    |
| Diabetes                     | 5 (36%)          | 7 (16%)              | .241    |
| Hyperlipidemia               | 5 (39%)          | 19 (44%)             | .667    |
| Current smoker               | 5 (36%)          | 24 (56%)             | .191    |
| Systolic BP (mmHg)           | 146.36±19.76     | 125.09±18.72         | <.001   |
| Diastolic BP (mmHg)          | 83.07±16.76      | 74.53±11.77          | .039    |
| LVEF, %                      | 65.37±9.24       | 63.12±10.72          | .622    |
| **Laboratory tests**         |                  |                      |         |
| Troponin I (ng/mL)           | 1.18±2.78        | 1.37±3.77            | .940    |
| CK-MB (UL)                   | 16.92±7.57       | 17.35±9.05           | .938    |
| Serum creatinine of pre-PCI (µmol/L) | 126.22±36.59 | 81.08±13.20 | <.001 |
| Serum creatinine of post-PCI (µmol/L) | 1.62±0.39   | 0.96±0.16 | <.001 |
| Serum cystatin C of post-PCI (mg/L) | 43.61±10.82 | 86.80±14.24 | <.001 |
| Serum cystatin C of pre-PCI (mg/L) | 138.79±42.50 | 82.39±12.43 | <.001 |
| eGFR (Scr-cys) of pre-PCI (ml/min/1.73 m²) | 42.21±15.56 | 86.17±14.23 | <.001 |
| eGFR (Scr-cys) of post-PCI (ml/min/1.73 m²) | 42.92 (1434–4994) | 2523 (1840–3232) | .911 |
| Ang-2 of post-PCI (pg/mL)    | 2851 (1720–4296) | 1552 (1043–2438) | .013 |
| Ang-2 of pre-PCI (pg/mL)     | 2438 (1434–4994) | 2523 (1840–3232) | .013 |
| **Angiographic characteristics** | 2.43±0.94 | 2.37±0.95 | .821 |
| No. of lesion vessels         | 11 (79%)         | 33 (77%)             | -       |
| Multivessel disease           | 2 (14%)          | 5 (12%)              | -       |
| LM disease                    | 14 (100%)        | 38 (88%)             | .428    |
| LAD disease                   | 10 (71%)         | 31 (72%)             | -       |
| LCx disease                   | 8 (57%)          | 28 (63%)             | -       |
| No. of treated vessels        | 1.36±0.50        | 1.49±0.63            | .576    |
| **Medications**               |                  |                      |         |
| Aspirin                       | 14 (100%)        | 43 (100%)            | NA      |
| Clopidogrel                   | 14 (100%)        | 43 (100%)            | NA      |
| Beta blocker                  | 13 (93%)         | 41 (95%)             | -       |
| Nitrates                      | 11 (79%)         | 35 (81%)             | -       |
| ACEI/ARB                      | 13 (85%)         | 40 (93%)             | -       |
| Statin                        | 14 (100%)        | 43 (100%)            | NA      |
| Diuretic                      | 3 (21%)          | 5 (12%)              | .635    |
| Calcium Channel Blockers      | 5 (36%)          | 4 (9%)               | .053    |

Data are displayed as mean±SD or n (%), aside from the Ang-2 levels shown as median (IQR). ACEI/ARB=angiotensin converting enzyme inhibitor/angiotensin receptor blocker, BMI=body mass index, CK-MB=creatine kinase MB form, LAD=left anterior descending coronary artery, LCx=left circumflex coronary artery, LM=left main coronary artery, LVEF=left ventricular ejection fraction, NA=not applicable, RCA=right coronary artery.

(2) Serum Ang-2 levels in non-CKD patients decrease significantly after PCI, while in CKD patients, serum angiopeit-nin-2 levels have no significant change after PCI.
protein covalently bound to neutrophil gelatinase, has been recognized as the earliest biomarker of AKI for now. The serum NGAL levels can rise within 2h after AKI and has been demonstrated to be highly correlated with the subsequent increased Scr levels. In addition, its prognostic role for adverse cardiovascular events is also of great value. But, to date, we haven’t found any data on the role of Ang-2 in CIN after PCI.

Figure 1. The change of serum Ang-2 levels after PCI in non-CKD group or CKD group.

Figure 2. Correlation of serum Ang-2 levels of post-PCI with the renal-function parameters of pre- or post-PCI (Spearman rank correlation test).
In patients with acute pancreatitis, increased serum Ang-2 concentrations are correlated with deteriorated renal function in the early phase, which indicates the potential role of Ang-2 as a predictor of acute pancreatic-renal syndrome. In critically ill patients, higher plasma Ang-2 concentrations are associated with higher risk of AKI. In acute myocardial infarction, the Ang-2 levels of day 1 can predict the development of AKI, and its levels are being a rising tendency over time in patients with AKI compared with those without. Therefore, given the strong link to the renal function, Ang-2 of post-PCI may also have potential to be the early biomarker of CIN. Ang-2 is stored in endothelial Weibel-Palade bodies and can be rapidly released through endothelial activation. The only known inhibitor of Ang-2 exocytosis from Weibel-Palade bodies is nitric oxide, which has decreased availability in patients with CIN. Besides, the vasoconstriction induced by contrast agent can lead to the reduction in renal blood flow, which results in the ischemia of medulla and release of ROS. These pathophysiology mechanisms may make the serum Ang-2 level not decrease significantly or even increase after PCI. Although this study didn’t provide direct evidence that Ang-2 of post-PCI can predict the CIN because of the small sample size, we still show highly association of serum Ang-2 levels of post-PCI with the renal-function parameters of post-PCI. Our blood samples were collected within 24 to 48 h after PCI. Further studies need to be done to investigate the relation between the Ang-2 levels of post-PCI in earlier phase and the subsequent occurrence of CIN.

It is well known that CKD patients (even in the lower stages) are more likely to develop CVD than people with a normal kidney function. The classical risk factors sometimes not only fail to predict cardiovascular burden but also show a reverse epidemiology in CKD. Recently, there is growing evidence that one of the principal pathophysiological mechanisms involved in the association of CKD with CVD may be the endothelial dysfunction. The impairment of endothelial function is the initial mechanism that can lead to atherosclerosis. Many risk factors which can affect endothelial function, such as diabetes, obesity, hypertension, and so on, can be found in association with CKD. Besides the common risk factors, the pathophyslogic mechanism of CKD can also directly influence the systemic endothelial functions in multiple ways, such as activation of the renin-angiotensin system, elevation of asymmetric dimethylarginine, increase of circulating cytokines, and so on. Ang-2, which can result in impaired endothelial integrity and function, has recently been shown to possess pro-atherosclerotic effects. Despite that many studies have respectively reported the vital role of Ang-2 in disease of CVD or CKD, the exactly pathophysiological mechanisms of Ang-2 under the systemic angle are still unclear. Ang-2 may be an important mediator which can enhance systemic vascular burden rather than a simple biomarker of endothelial dysfunction merely reflecting the severity of the disease. Ang-2 is able to sensitize endothelial cells towards TNF-α, which can stimulate the upregulation of related adhesion molecules. These molecules can encourage the migration of monocytes into the arterial wall through the endothelium, promote extracellular matrix degradation and make the plaque vulnerable. It is recently reported that Ang-2 is an independent predictor of major adverse cardiovascular events in CKD patients. In addition, previous studies have shown that the elevated Ang-2 level is an indicator of abnormal cardiac structure and vascular atherosclerotic burden in patients with CKD, which supported our hypothesis that the Ang-2 released from 1 dysfunctional organ may accelerate the disease progress of distant organ. On the other hand, in patients with CAD, the Ang-2 released from the heart may also exacerbate the renal function by enhancing the glomerular endothelial apoptosis, aggravating the tissue edema and leading to the albuminuria. Therefore, altered angiopoietin/Tie-2 system may cause a cascade leading to the systemic endothelial dysfunction and subsequent organs dysfunction. However, the exact mechanisms need to be further investigated. Ang-2 may become a novel target to develop therapeutic strategies against CVD or CKD in the future.

Of note, some other mediators have been recently reported probably to be involved in the pathophysiological mechanism accounting for the high risk of CVD in CKD patients. For instance, microRNAs (miRNAs), the small non-coding RNA molecules that function in RNA silencing and post-transcriptional regulation of gene expression, have been reported to contribute to both the induction and progression of CKD. In addition, circulating miRNAs can be used as diagnostic or prognostic biomarkers in cardiovascular disease, and may have putative function as long-distance communicators enhancing systemic burden. Neopterin, a marker of inflammation and of immune system activation, is synthesized by activated macrophages. After exclusion of patients with known cardiovascular disease, serum neopterin levels are elevated and correlated with the severity of CKD. Besides, there is also a strong association of neopterin with CVD. Studies suggested that it can induce a pro-atherothrombotic phenotype in human coronary endothelial cells and can be used as a biomarker predicting the adverse cardiovascular events. Urotensin II (UT-II), which plays an important role in CKD, is involved with endothelial dysfunction and coronary thrombosis. It probably represents a key link between CKD and CAD. It may also have potential to be a biomarker of CIN, since one study showed that serum UT-II levels of post-PCI are significantly correlated with the amount of contrast media in patients undergoing PCI. Oddly, plasma UTN is found to be an inverse predictor of cardiovascular mortality in patients with CKD. Therefore, it will be intriguing to further assess the relationship of Ang-2 with these potential mediators after PCI, and their associations with the occurrence of CIN and subsequent adverse cardiovascular events.

However, there are some limitations to our study. First, because of the small sample size, how the Ang-2 levels will change in CIN remains to be further investigated. Second, we excluded the patients of STEMI and all of our subjects have no renal failure or uremia, which may underestimate the influence of renal function on serum Ang-2 levels. Therefore, studies on a larger sample size should be performed in the future.

Author contributions

Conceptualization: Chun Gui.
Data curation: Wen Jian, Lang Li, Xiao-Min Wei, Chun Gui.
Formal analysis: Wen Jian, Lang Li, Jia-Hui Guan, Chun Gui.
Funding acquisition: Chun Gui.
Investigation: Wen Jian, Xiao-Min Wei, Chun Gui.
Methodology: Jia-Hui Guan, Chun Gui.
Project administration: Lang Li, Xiao-Min Wei, Chun Gui.
Resources: Lang Li, Chun Gui.
Software: Wen Jian, Jia-Hui Guan, Guo-Liang Yang, Chun Gui.
Supervision: Lang Li, Chun Gui.
Validation: Wen Jian, Lang Li, Chun Gui.
Visualization: Wen Jian, Lang Li, Chun Gui.
Writing – original draft: Wen Jian.
Writing – review & editing: Wen Jian, Chun Gui.
References

[1] Matsunaga T, Warthier DC, Tessmer J, et al. Expression of VEGF and angiopoietin-1 and -2 during ischemia-induced coronary angiogenesis. Am J Physiol Heart Circ Physiol 2003;285:H152-8.

[2] Fiedler U, Augustin HG. Angiopoietin-1: a link between angiogenesis and inflammation. Trends Immunol 2006;27:552-8.

[3] Kim I, Kim HG, So JN, et al. Expression of VEGF and angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3’-Kinase/Akt signal transduction pathway. Circ Res 2000;86:24-9.

[4] Masionipiere PC, Sari C, Jones PF, et al. Angiopoietin-2, a natural Antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997;277:55-60.

[5] Fiedler U, Scharpfenecker M, Knoll S, et al. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood 2004;103:4150-6.

[6] Fam NP, Arab S, Billia F, et al. Increased myocardial expression of angiopoietin-2 in patients undergoing urgent surgical revascularization for acute coronary syndromes. Can J Cardiol 2010;26:365-70.

[7] Zeng ZY, Guo C, Li L, et al. Effects of percutaneous coronary intervention on serum angiopoietin-2 in patients with coronary heart disease. Biomarkers 2012;17:745-9.

[8] Wang X, Yong H, Mi L, et al. Changes and significance of serum angiopoietin-2 levels in patients with coronary heart disease. Biomarkers 2015;13:473-541.

[9] Major RW, Cheng M, Grant RA, et al. Cardiorenal disease associated factors in chronic kidney disease: a systematic review and meta-analysis. PLoS One 2011;11:e192895.

[10] Tsai YC, Lee CS, Chiu YW, et al. Angiopoietin-2 as a prognostic biomarker of major adverse cardiovascular events and all-cause mortality in chronic kidney disease. PLoS One 2015;10:e0135181.

[11] Schole A, Plate KH, Reiss Y. Angiopoietin-2: a multifaceted cytokine that functions in both angiogenesis and inflammation. Am J Physiol Renal Physiol 2015;305:F901-10.

[12] Pichiule F, Chavez JC, LaManna JC. Hypoxic regulation of angiopoietin-2 expression in endothelial cells. J Biol Chem 2004;279:12171-80.

[13] Kim I, Kim JH, Byo YS, et al. Tumor Necrosis Factor-a upregulates angiopoietin-2 in human umbilical vein endothelial cells. Biochem Biophys Res Commun 2000;269:361-5.

[14] David S, Kümper P, Lukasz A, et al. Circulating angiopoietin-2 levels increase with progress of chronic kidney disease. Nephrol Dial Transplant 2010;25:2571-6.

[15] Chang F, Lai TS, Chiang CK, et al. Angiopoietin-2 is associated with albuminuria and microalbuminuria in chronic kidney disease. PLoS One 2013;8:e54656.

[16] Hennings A, Hannemann A, Retig R, et al. Circulating angiopoietin-2 and its soluble receptor tie-2 concentrations are related to renal function in two population-based cohorts. PLoS One 2016;11:e0166492.

[17] Yuan HT, Tipping PG, Li XZ, et al. Angiopoietin correlates with glomerular capillary loss in anti-glomerular basement membrane glomerulonephritis. Kidney Int 2002;62:1078-89.

[18] Khairou M, Van DPP, de Vries DK, et al. Renal ischaemia-reperfusion induces a dysbalance of angiopoietins, accompanied by proliferation of pericytes and fibrosis. Am J Physiol Renal Physiol 2013;305:F901-10.

[19] Levey AS. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012;367:20.

[20] Azzalini L, Spagnoli V, Ly H. Contrast-induced nephropathy: from pathophysiology to preventive strategies. Can J Cardiol 2016;32:247-55.

[21] Bachorzewska-Gajewska H, Malyzko J, Stawiarska E, et al. Neutrophil-gelatinase-associated lipocalin and renal function after percutaneous coronary interventions. Am J Nephrol 2006;26:287-92.

[22] Michael H, Rinaldo B, Prasad D, et al. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis 2009;54:987-9.

[23] Sporek M, Dumnicka P, Galabladzinska A, et al. Angiopoietin-2 is an early indicator of acute pancreatic-renal syndrome in patients with acute pancreatitis. Mediat Inflamm 2016;2016:1-7.

[24] Robinson-Cohen C, Katz R, Price BL, et al. Association of markers of endothelial dysregulation Ang1 and Ang2 with acute kidney injury in critically ill patients. Crit Care 2016;20:1-8.

[25] Lu K, Lee KT, Chang CH, et al. Elevated plasma thrombomodulin and angiopoietin-2 predict the development of acute kidney injury in patients with acute myocardial infarction. Crit Care 2014;18:R100.

[26] Piss J, Fuernau G, Denks D, et al. Angiopoietin-2 in acute myocardial infarction complicated by cardiogenic shock—a biomarker substudy of the IABP-SHOCK II-Trial. Eur J Heart Fail 2015;17:1152-60.

[27] Märtens A, Morrell C, Yamazaki T. Regulation of Weibel-Palade body exocytosis. Trends Cardiovasc Med 2005;15:302-8.

[28] Kilpatrick RD, McAllister CJ, Kovesdy CP, et al. Association between serum lipids and survival in hemodialysis patients and impact of race. J Am Soc Nephrol 2007;18:293-303.

[29] Endemann DH, Schiffrin EL. Endothelial dysfunction. J Am Soc Nephrol 2004;15:1983-92.

[30] Schiffrin EL, Lipman ML, Manno JF. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007;116:85-97.

[31] Troilo A, Gollek J. Angiopoietins, abdominal aortic aneurysm and atherosclerosis. Atherosclerosis 2011;214:237-43.

[32] Fiedler U, Reiss Y, Scharpfenecker M, et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alfa and has a crucial role in the induction of inflammation. Nature Med 2006;12:235-9.

[33] Tsai Y, Lee C, Chiu Y, et al. Angiopoietin-2 and angiotensin-1 and -2 in cardiovascular disease in Chronic Kidney Disease. Sci Rep 2016;6:39400.

[34] David S, Kümper P, Hellpap J, et al. Angiopoietin 2 and cardiovascular disease in dialysis and kidney transplantation. Am J Kidney Dis 2009;53:770-8.

[35] Davis B, Dei Cas A, Long D, et al. Podocyte-specific expression of angiopoietin-2 causes proteinuria and apoptosis of glomerular endothelia. J Am Soc Nephrol 2007;18:2320-9.

[36] Pieza T, Ariela R, Giuseppe R. MicroRNAs in kidney physiology and disease. Nat Rev Nephrol 2015;11:23-33.

[37] Fichtlscherer S, Zeiber AM, Dimmeler S. Circulating MicroRNAs: biomarkers or mediators of cardiovascular diseases? Arterioscler Thromb Vasc Biol 2011;31:2383-90.

[38] Yadav AK, Sharma V, Jha V. Association between serum neopterin and inflammatory activation in chronic kidney disease. Mediators Inflamm 2012;2012:476979.

[39] Mario P, Plinio C, Salvatore DR, et al. The role of neopterin in cardiovascular disease. Monaldi Arch Chest Dis 2007;68:68-73.

[40] Cirillo P, Pacileo M, De RS, et al. Neopterin induces pro-atherothrombotic phenotype in human coronary endothelial cells. J Thromb Haemost 2010;8:2248-56.